Targeting mitochondrial bioenergetics for alzheimer's prevention and treatment

Current Pharmaceutical Design

Volumn 17, Issue 31, 2011, Pages 3474-3479

  Yao, Jia ^a   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Bioenergetics; Hypometabolism; Ketogenesis; Mitochondria; Oxidative stress; References

Indexed keywords

ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASCORBIC ACID; BAPINEUZUMAB; CURCUMIN; HOMOTAURINE; KETONE BODY; POLYCLONAL ANTIBODY; PRESENILIN 1; PRESENILIN 2; PYRUVATE DEHYDROGENASE COMPLEX; REACTIVE OXYGEN METABOLITE; RESVERATROL; SEMAGACESTAT; TARENFLURBIL; THIOCTIC ACID;

ALZHEIMER DISEASE; ARTICLE; BIOENERGY; BRAIN METABOLISM; BRAIN MITOCHONDRION; DISEASE COURSE; ENERGY RESOURCE; GLUCOSE METABOLISM; HUMAN; ILLNESS TRAJECTORY; MENINGOENCEPHALITIS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CENTRAL NERVOUS SYSTEM AGENTS; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS;

EID: 80055070859     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798072517     Document Type: Article

References (97)

1. Association As. Alzheimer's Disease Facts and Figures 2011: 12.
2. Fassbender K, Masters C, Beyreuther K. Alzheimer's disease: mo-lecular concepts and therapeutic targets. Naturwissenschaften 2001;88: 261-7.
3. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K,Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.
4. Chen K, Reiman EM, Alexander GE, et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry 2007; 164: 916-21.
5. Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alz- heimer's disease: the need for a paradigm shift. Neuron 2011; 69: 203-13.
6. Learning from failure. Nature reviews. Drug discovery 2010; 9: 499.
7. Armstrong RA. The pathogenesis of Alzheimer's disease: a re- evaluation of the amyloid cascade hypothesis. Int J Alzheimer's disease 2011; 2011.
8. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimer's disease: JAD 2006; 9: 151-3.
9. Sommer B. Alzheimer's disease and the amyloid cascade hypothe-sis: ten years on. Current opinion in pharmacology 2002; 2: 87-92.
10. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992; 256: 184-5.
11. Simon AM, Frechilla D, del Rio J. [Perspectives on the amyloid cascade hypothesis of Alzheimer's disease]. Revista de neurologia 2010; 50: 667-75.
12. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. The international J biochemistry & cell biol- ogy 2009; 41: 1261-8.
13. Gibson GE, Shi Q. A mitocentric view of Alzheimer's disease suggests multi-faceted treatments. J Alzheimer's disease: JAD 2010; 20 Suppl 2: S591-607.
14. Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the amyloid cascade? Alzheimer's research & therapy 2010; 2: 5.
15. Imbimbo BP, Giardina GA. gamma-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappoint- ments and Hopes. Current topics in medicinal chemistry 2011.
16. Brinton RD. Estrogen regulation of glucose metabolism and mito-chondrial function: therapeutic implications for prevention of Alz-heimer's disease. Adv Drug Deliv Rev 2008; 60: 1504-11.
17. Magistretti PJ. Neuron-glia metabolic coupling and plasticity. J Exp Biol 2006; 209: 2304-11.
18. Wallace DC. A mitochondrial paradigm of metabolic and degen- erative diseases, aging, and cancer: a dawn for evolutionary medi- cine. Annu Rev Genet 2005; 39: 359-407.
19. Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 2009; 218: 308-15.
20. Mosconi L, Mistur R, Switalski R, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alz- heimer disease. Neurology 2009; 72: 513-20.
21. Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010; 1802: 212-20.
22. Moreira PI, Cardoso SM, Santos MS, Oliveira CR. The key role of mitochondria in Alzheimer's disease. J Alzheimer's disease: JAD 2006; 9: 101-10.
23. Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coen- zyme A-acetylating enzymes in Alzheimer's disease: possible cho- linergic 'compartment' of pyruvate dehydrogenase. Neuroscienceletters, 1980; 18: 105-10.
24. Blass JP. The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome. Ann N Y Acad Sci 2000; 924: 170-83.
25. Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Annals of neurology, 1983; 13: 72-8.
26. Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thia-mine-dependent enzymes in the brains and peripheral tissues of pa-tients with Alzheimer's disease. Archives of neurology, 1988; 45:836-40.
27. Parker WD, Jr. Cytochrome oxidase deficiency in Alzheimer's disease. Annals of the New York Academy of Sciences, 1991; 640: 59-64.
28. Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. Cyto- chrome c oxidase is decreased in Alzheimer's disease platelets.Neurobiology of aging 2004; 25: 105-10.
29. Khan SM, Cassarino DS, Abramova NN, et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Annals of neurology 2000; 48: 148-55.
30. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J neuroscience research 2007; 85: 3416-28.
31. Takuma K, Yao J, Huang J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 2005; 19: 597-8.
32. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004; 304:448-52.
33. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and lzheimer's disease. Trends Mol Med 2008; 14: 45-53.
34. Cardoso SM, Santos S, Swerdlow RH, Oliveira CR. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2001; 15: 1439-41.
35. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxic-ity. J neurochemistry 2004; 89: 1417-26.
36. Silva DF, Esteves AR, Arduino DM, Oliveira CR, Cardoso SM. Amyloid-beta-Induced Mitochondrial Dysfunction Impairs the Autophagic Lysosomal Pathway in a Tubulin Dependent Pathway. J Alzheimer's disease: JAD 2011.
37. Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimer's disease: JAD 2010; 20 Suppl 2: S265-79.
38. Swerdlow RH, Khan SM. A mitochondrial cascade hypothesis for sporadic Alzheimer's disease. Medical hypotheses 2004; 63: 8-20.
39. Swerdlow RH, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Experimental neurology 2009; 218: 308-15.
40. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease0. Proc Natl Acad Sci U S A 2009; 106: 14670-5.
41. Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, Valla J. Regional cerebral glucose uptake in the 3xTG model of Yao and Brinton Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain research 2010; 1347: 179-85.
42. Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunc- tion: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiology of aging 2009; 30: 1574-86.
43. Chou JL, Shenoy DV, Thomas N, et al. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J proteomics 2011; 74: 466-79.
44. Diana FF, Silva Esteves AR, Oliveira CR, Cardoso SM. Mitochon- dria: The Common Upstream Driver of Abeta and Tau Pathology in Alzheimer s Disease. Current Alzheimer research 2011.
45. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 18670-5.
46. Ishii K, Sasaki M, Kitagaki H, et al. Reduction of cerebellar glu- cose metabolism in advanced Alzheimer's disease. J Nucl Med, 1997; 38: 925-8.
47. Spulber G, Niskanen E, Macdonald S, et al. Whole brain atrophy rate predicts progression from MCI to Alzheimer's disease. Neuro-biol Aging 2008.
48. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 10966-71.
49. Reiman EM, Chen K, Alexander GE, et al. Functional brain ab- normalities in young adults at genetic risk for late-onset Alz-heimer's dementia. Proceedings of the National Academy of Sci-ences of the USA 2004; 101: 284-9.
50. Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of ag-ing 2008; 29: 676-92.
51. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European J nuclear medicine and mo-lecular imaging 2009; 36: 811-22.
52. Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011.
53. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60: 1374-7.
54. Vaishnavi SN, Vlassenko AG, Rundle MM, Snyder AZ, Mintun MA, Raichle ME. Regional aerobic glycolysis in the human brain. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 17757-62.
55. Vlassenko AG, Vaishnavi SN, Couture L, et al. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposi-tion. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 17763-7.
56. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nature neurosci-ence 2011.
57. Yao J, Hamilton RT, Cadenas E, Brinton RD. Decline in mito- chondrial bioenergetics and shift to ketogenic profile in brain dur-ing reproductive senescence. Biochim Biophys Acta 2010; 1800:1121-6.
58. Hoyer S, Nitsch R, Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect, 1991; 3: 1-14.
59. Morris AA. Cerebral ketone body metabolism. J inherited meta- bolic disease 2005; 28: 109-21.
60. Kuczynski B, Targan E, Madison C, et al. White matter integrity and cortical metabolic associations in aging and dementia. Alz-heimer's & dementia: the J the Alzheimer's Association 2010; 6:54-62.
61. Agosta F, Pievani M, Sala S, et al. White matter damage in Alz-heimer disease and its relationship to gray matter atrophy. Radiol-ogy 2011; 258: 853-63.
62. Carmichael O, Schwarz C, Drucker D, et al. Longitudinal changesin white matter disease and cognition in the first year of the Alz-heimer disease neuroimaging initiative. Archives of neurology 2010; 67: 1370-8.
63. Gonzalez-Lima F, Berndt JD, Valla JE, Games D, Reiman EM.Reduced corpus callosum, fornix and hippocampus in PDAPP transgenic mouse model of Alzheimer's disease. Neuroreport 2001; 12: 2375-9.
64. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant tar- geted therapeutic strategies for Alzheimer's disease. J Alzheimer's disease: JAD 2010; 20 Suppl 2: S633-43.
65. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-95.
66. Beal MF. Mitochondria take center stage in aging and neurodegen- eration. Ann Neurol 2005; 58: 495-505.
67. Park LC, Zhang H, Sheu KF, et al. Metabolic impairment induces oxidative stress, compromises inflammatory responses, and inacti-vates a key mitochondrial enzyme in microglia. J neurochemistry, 1999; 72: 1948-58.
68. Starkov AA, Fiskum G, Chinopoulos C, et al. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. The J neuroscience: the official J the Society for Neuro-science 2004; 24: 7779-88.
69. Atamna H, Frey WH, 2nd. Mechanisms of mitochondrial dysfunc-tion and energy deficiency in Alzheimer's disease. Mitochondrion 2007.
70. Nunomura A, Chiba S, Lippa CF, et al. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiology of disease 2004; 17: 108-13.
71. Reddy PH. Mitochondrial oxidative damage in aging and Alz-heimer's disease: implications for mitochondrially targeted antioxi-dant therapeutics. J Biomed Biotechnol 2006; 2006: 31372.
72. Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA, Perry G. RNA oxidation in Alzheimer disease and related neurodegenera-tive disorders. Acta neuropathologica 2009; 118: 151-66.
73. Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 2007;145: 1233-48.
74. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alz-heimer's disease. J Neurochem 2005; 93: 953-62.
75. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. The J neuroscience: the official J the Society for Neuroscience 2001; 21: 4183-7.
76. Rhein V, Song X, Wiesner A, et al. Amyloid-beta and tau synergis-tically impair the oxidative phosphorylation system in triple trans-genic Alzheimer's disease mice. Proceedings of the National Acad-emy of Sciences of the United States of America 2009; 106: 20057-62.
77. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J neuropathology and experi-mental neurology 2001; 60: 759-67.
78. Moreira PI, Santos MS, Seica R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007; 257: 206-14.
79. Li F, Calingasan NY, Yu F, et al. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J neuro-chemistry 2004; 89: 1308-12.
80. Extance A. Alzheimer's failure raises questions about disease- modifying strategies. Nat Rev Drug Discov 2010; 9: 749-51.
81. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma- secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals neurology 2009; 66: 48-54.
82. Raybon JJ, Albright CF. In response to a gamma-secretase inhibi- tor decreases amyloid-beta production in the central nervous sys- tem. Annals of neurology 2010; 67: 143-4; author reply 144-5.
83. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC medicine 2009; 7: 7.
84. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pa- thology in an Alzheimer transgenic mouse. The J neuroscience: the official J the Society for Neuroscience 2001; 21: 8370-7.
85. Conte V, Uryu K, Fujimoto S, et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repeti- tive concussive brain injury. J neurochemistry 2004; 90: 758-64.
86. Brewer GJ. Why vitamin E therapy fails for treatment of Alz- heimer's disease. J Alzheimer's disease: JAD 2010; 19: 27-30.
87. Bartzokis G, Sultzer D, Lu PH, Nuechterlein KH, Mintz J, Cum- mings JL. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical disconnection in ag- ing and Alzheimer's disease. Neurobiol Aging 2004; 25: 843-51.
88. Packer L, Cadenas E. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. J clinical biochemis- try and nutrition 2011; 48: 26-32.
89. Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Maram- baud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC neuroscience 2008; 9 Suppl 2: S6.
90. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pa- thology in a transgenic model of Alzheimer's disease. Neurochem- istry international 2009; 54: 111-8.
91. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. The J biological chemistry 2005; 280: 37377-82.
92. Li H, Yan Z, Zhu J, Yang J, He J. Neuroprotective effects of res- veratrol on ischemic injury mediated by improving brain energy metabolism and alleviating oxidative stress in rats. Neuropharma- cology 2011; 60: 252-8.
93. Wollen KA. Alzheimer's disease: the pros and cons of pharmaceu- tical, nutritional, botanical, and stimulatory therapies, with a dis- cussion of treatment strategies from the perspective of patients and practitioners. Alternative medicine review: a J clinical therapeutic 2010; 15: 223-44.
94. Auestad N, Korsak RA, Morrow JW, Edmond J. Fatty acid oxida- tion and ketogenesis by astrocytes in primary culture. J Neuro- chem, 1991; 56: 1376-86.
95. Guzman M, Blazquez C. Ketone body synthesis in the brain: possi- ble neuroprotective effects. Prostaglandins Leukot Essent Fatty Ac- ids 2004; 70: 287-92.
96. Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics: the J the American Society for Ex- perimental NeuroTherapeutics 2008; 5: 470-80.
97. Jia Yao SC, Zisu Mao, Enrique Cadenas, Roberta Diaz Brinton. 2- Deoxy-D-Glucose Treatment Induces Ketogenesis, Sustains Mito- chondrial Function, and Reduces Pathology in Female Mouse Model of Alzheimer's Disease. PLoS ONE 2011; 6.